Adaptive Biotechnologies announces growing interventional use of clonoSEQ test

Adaptive Biotechnologies (ADPT) announced growing interventional use of its clonoSEQ test among the 90 abstracts featuring clonoSEQ data at the 67th American Society of Hematology, ASH, Annual Meeting and Exposition, taking place Dec. 6-9, 2025, in Orlando. Notably, 17 abstracts utilizing Adaptive’s clonoSEQ test exemplify how next-generation sequencing-based measurable residual disease, MRD, status is guiding clinical actions to improve blood cancer patient care. Practice-changing data from the phase II EndRAD study support the use of NGS MRD status prior to allogeneic hematopoietic cell transplantation to guide the selection of non-total body irradiation conditioning approaches to reduce long-term toxicities in children and young adults with B-cell acute lymphoblastic leukemia, without compromising outcomes. The study showed event-free and overall survival outcomes in 51 patients who were NGS MRD negative and received a non-TBI regimen. The study also enrolled a comparator cohort who received TBI and showed equivalent survival in NGS MRD negative patients who received TBI compared to non-TBI approaches.